Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to include a new vulnerability disclosure from HHS and has revised its version number to v2.16.8, replacing the previous version v2.16.6. Additionally, the dates have been updated to reflect new entries for July 17 and July 18, 2025.SummaryDifference0.4%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.0%
- Check20 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.5%
- Check27 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.6%
- Check34 days agoNo Change Detected
- Check41 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check48 days agoChange DetectedThe page has updated its date information, adding several new dates for June 2025 while removing older dates from March and April 2025.SummaryDifference0.4%
Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.